Real-world treatment patterns and outcomes of patients with HER2+ ...
Eligible studies were randomised controlled trials (RCTs) that compared a treatment duration of 6 months or less (?6 months) of trastuzumab or ...
MANAGEMENT OF HER2-POSITIVE BREAST CANCERThis study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with. HER2-TARGETED THERAPIES IN BREAST CANCERBackground: Trastuzumab deruxtecan (T-DXd) currently represents the standard of care for the treatment of patients with metastatic HER2-positive. (HER2+) breast ... Systemic Therapy of HER2-positive Breast Cancer - OncologyPROtreatment options. ? T-D is a HER2-targeted treatment that fills an unmet need in the 2nd line treatment. It is believed to be a therapeutic advancement due ...
Autres Cours:
